Generalized LFT-Based Representation of Parametric Uncertain Models

In this paper, we introduce a general descriptor-type linear fractional transformation (LFT) representation of rational parametric matrices. This is a generalized representation of arbitrary rationally dependent multivariate functions in LFT-form. As applications, we develop explicit LFT-realizations of the transfer-function matrix of a linear descriptor system whose state-space matrices depend rationally on a set of uncertain parameters. The resulting descriptor LFT-based uncertainty models generally have smaller orders than those obtained by using the standard LFT-based modelling approach. An example of an uncertain vehicle model illustrates the capability of the method

Reply to the Comment of den Hartog and van Wees on "Conductance Fluctuations in Mesoscopic Normal-Metal/Superconductor Samples"

In their comment cond-mat/9710285 [Phys. Rev. Lett. 80, 5024 (1998)] den Hartog and van Wees (HW) raise objections against our analysis of the experimental data presented in cond-mat/9708162 [Phys. Rev. Lett. 79, 1547 (1997)]. According to HW, we did not account for the quantum phase incoherence introduced by the Niobium compounds of the investigated Nb/Au hybrid samples. Here we show that and why this criticism is not justified. Some difficulties associated with a precise determination of the coherence lengths are discussed. It is discussed why these uncertainties do not have a qualitative impact on the results reported in our paper.Comment: Reply to the comment cond-mat/9710285 by den Hartog and van Wees; 1 page REVTE

Comment on "Conductance fluctuations in mesoscopic normal-metal/superconductor samples"

Recently, Hecker et al. [Phys. Rev. Lett. 79, 1547 (1997)] experimentally studied magnetoconductance fluctuations in a mesoscopic Au wire connected to a superconducting Nb contact. They claimed to have observed an enhancement of the rms magnitude of these conductance fluctuations in the superconducting state (rms(Gns)) relative to that in the normal state (rms(Gn)) by a factor of 2.8. In this comment, we argue that the measured rms(Gns) is NOT significantly enhanced compared to rms(Gn) when we correct for the presence of an incoherent series resistance from the contacts, which is different when Nb is in the superconducting or normal state.Comment: 1 pag

Observation of the Pairing Gap in a Strongly Interacting Fermi Gas

We study fermionic pairing in an ultracold two-component gas of $^6$Li atoms by observing an energy gap in the radio-frequency excitation spectra. With control of the two-body interactions via a Feshbach resonance we demonstrate the dependence of the pairing gap on coupling strength, temperature, and Fermi energy. The appearance of an energy gap with moderate evaporative cooling suggests that our full evaporation brings the strongly interacting system deep into a superfluid state.Comment: 18 pages, 3 figure

Performance and evaluation of two liquid-metal pumps for sodium-potassium service

Performance tests on liquid metal pumps for sodium potassium loop

Exploring the BEC-BCS Crossover with an Ultracold Gas of 6^6Li Atoms

We present an overview of our recent measurements on the crossover from a Bose-Einstein condensate of molecules to a Bardeen-Cooper-Schrieffer superfluid. The experiments are performed on a two-component spin-mixture of $^6$Li atoms, where a Fesh\-bach resonance serves as the experimental key to tune the s-wave scattering length and thus to explore the various interaction regimes. In the BEC-BCS crossover, we have characterized the interaction energy by measuring the size of the trapped gas, we have studied collective excitation modes, and we have observed the pairing gap. Our observations provide strong evidence for superfluidity in the strongly interacting Fermi gas.Comment: Proceedings of ICAP-2004 (Rio de Janeiro). Review on Innsbruck BEC-BCS crossover experiments with updated Feshbach resonance positio

The effects of donepezil in Alzheimer's disease - Results from a multinational trial

Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer's disease (AD). The current trial was undertaken to investigate further the efficacy and safety of donepezil, in a multinational setting, in patients with mild to moderately severe AD. This 30-week, placebo-controlled, parallel-group study consisted of a 24-week, double-blind treatment phase followed by a 6-week, single-blind, placebo washout. Eight hundred and eighteen patients with mild to moderately severe AD were randomly allocated to treatment with single, daily doses of 5 or 10 mg donepezil, or placebo. The two primary efficacy measures were: a cognitive performance test, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and a global evaluation, the Clinician's Interview-Based Impression of Change with caregiver input (CIBIC plus). Secondary outcome measures included the Sum of the Boxes of the Clinical Dementia Rating Scale (CDR-SB), a modified Interview for Deterioration in Daily living activities in Dementia (IDDD) and a patient-rated quality of life assessment. Statistically significant improvements in cognitive and global function were observed, as evaluated by ADAS-cog and CIBIC plus, respectively, in both the 5 and 10 mg/day donepezil groups, compared with placebo. Treatment-associated changes were also observed in functional skills, as shown by improved scores on the CDR-SB and the complex-tasks component of the IDDD. A dose-response effect was evident, with the 10 mg/day donepezil group demonstrating greater benefits in all outcome measures than the 5 mg/day group. Donepezil was well tolerated by this patient population and did not produce any clinically significant laboratory test abnormalities. The results of this study confirm that donepezil is effective and well tolerated in treating the symptoms of mild to moderately severe AD

The Cold War is over. What now?

As you might imagine, the end of the Cold War has elicited an intense reexamination of the roles and missions of institutions such as the Los Alamos National Laboratory. During the past few years, the entire defense establishment has undergone substantial consolidation, with a concomitant decrease in support for research and development, including in areas such as materials. The defense industry is down-sizing at a rapid pace. Even universities have experienced significant funding cutbacks from the defense community. I view this as a profound time in history, bringing changes encompassing much more than just the defense world. In fact, support for science and technology is being reexamined across the board more completely than at any other time since the end of World War II